|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/13/20 SOBR Safe, Inc. 10-Q 3/31/19 52:3.3M Discount Edgar/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 387K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 21K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 21K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
14: R1 Document and Entity Information HTML 57K
39: R2 Condensed Consolidated Balance Sheets HTML 87K
44: R3 Condensed Consolidated Balance Sheets HTML 46K
(Parenthetical)
28: R4 Condensed Consolidated Statements of Operations HTML 54K
(Unaudited)
13: R5 Condensed Consolidated Statements of Changes in HTML 52K
Stockholders' Equity (Unaudited)
38: R6 Condensed Consolidated Statements of Cash Flows HTML 76K
(Unaudited)
43: R7 Organization, Operations and Summary of HTML 93K
Significant Accounting Policies
29: R8 Going Concern HTML 25K
12: R9 Related Party Transactions HTML 29K
17: R10 Notes Payable HTML 41K
23: R11 Derivative Liability HTML 25K
50: R12 Stock Warrants and Stock Options HTML 84K
36: R13 Common Stock HTML 19K
18: R14 Preferred Stock HTML 23K
25: R15 Commitments and Contingencies HTML 21K
51: R16 Subsequent Events HTML 54K
37: R17 Organization, Operations and Summary of HTML 93K
Significant Accounting Policies (Policies)
19: R18 Organization, Operations and Summary of HTML 29K
Significant Accounting Policies (Tables)
22: R19 Notes Payable (Tables) HTML 25K
46: R20 Derivative Liability (Tables) HTML 20K
40: R21 Stock Warrants and Stock Options (Tables) HTML 84K
15: R22 Organization Operations and Summary of Significant HTML 26K
Accounting Policies (Details)
31: R23 Organization Operations and Summary of Significant HTML 25K
Accounting Policies (Details Narrative)
47: R24 Going Concern (Details Narrative) HTML 58K
41: R25 Related Party Transactions (Details Narrative) HTML 138K
16: R26 Notes Payable (Details) HTML 30K
32: R27 Notes Payable (Details 1) HTML 27K
45: R28 Notes Payable (Details Narrative) HTML 93K
42: R29 Derivative Liability (Details) HTML 22K
35: R30 Derivative Liability (Details Narrative) HTML 45K
49: R31 Stock Warrants and Stock Options (Details) HTML 31K
27: R32 Stock Warrants and Stock Options (Details 1) HTML 61K
21: R33 Stock Warrants and Stock Options (Details 2) HTML 92K
34: R34 Stock Warrants and Stock Options (Details HTML 43K
Narrative)
48: R35 Common Stock (Details Narrative) HTML 27K
26: R36 Preferred Stock (Details Narrative) HTML 28K
20: R37 Commitments and Contingencies (Details Narrative) HTML 24K
33: R38 Subsequent Events (Details Narrative) HTML 114K
52: XML IDEA XML File -- Filing Summary XML 87K
30: EXCEL IDEA Workbook of Financial Reports XLSX 62K
6: EX-101.INS XBRL Instance -- imle-20190331 XML 983K
9: EX-101.CAL XBRL Calculations -- imle-20190331_cal XML 50K
11: EX-101.DEF XBRL Definitions -- imle-20190331_def XML 509K
8: EX-101.LAB XBRL Labels -- imle-20190331_lab XML 766K
10: EX-101.PRE XBRL Presentations -- imle-20190331_pre XML 672K
7: EX-101.SCH XBRL Schema -- imle-20190331 XSD 164K
24: ZIP XBRL Zipped Folder -- 0001477932-20-000170-xbrl Zip 131K
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of TransBiotec, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Charles Bennington, President of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
| (2) | Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: January 13, 2020 | By: |
| |
|
| ||
| Chief Executive Officer |
|
A signed original of this written statement required by Section 906 has been provided to TransBiotec, Inc. and will be retained by TransBiotec, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 1/13/20 | None on these Dates | ||
| For Period end: | 3/31/19 | |||
| List all Filings | ||||